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Acetaminophen (APAP) overdose can cause hepatotoxicity by 
inducing mitochondrial damage and subsequent necrosis in 
hepatocytes. Sirtuin2 (Sirt2) is an NAD＋-dependent deacetylase 
that regulates several biological processes, including hepatic 
gluconeogenesis, as well as inflammatory pathways. We show 
that APAP decreases the expression of Sirt2. Moreover, the 
ablation of Sirt2 attenuates APAP-induced liver injuries, such 
as oxidative stress and mitochondrial damage in hepatocytes. 
We found that Sirt2 deficiency alleviates the APAP-mediated 
endoplasmic reticulum (ER) stress and phosphorylation of the 
p70 ribosomal S6 kinase 1 (S6K1). Moreover, Sirt2 interacts 
with and deacetylates S6K1, followed by S6K1 phospho-
rylation induction. This study elucidates the molecular 
mechanisms underlying the protective role of Sirt2 inactivation 
in APAP-induced liver injuries. [BMB Reports 2019; 52(3): 
190-195]
INTRODUCTION
Drug-induced liver injury is a leading cause of acute liver 
failure. Therefore, the discovery of novel therapeutic targets for 
regulating the progression of liver injury is important (1). 
Acetaminophen (APAP) has been widely used to understand 
the mechanism of drug-induced hepatotoxicity as a major 
cause of liver damage.
APAP-mediated hepatotoxicity is caused by the cytochrome 
P450 (CYP) 1A2-, CYP2E1-, and CYP3A4-driven conversion of 
APAP into hepatotoxic metabolites (2-4). Moreover, APAP- 
induced hepatotoxicity is associated with oxidative stress 
induced by N-Acetyl-p-benzoquinone imine, a reactive 
metabolite of APAP (5) or by endoplasmic reticulum (ER) stress 
(6, 7). 
Sirtuins are NAD＋-dependent deacetylases with seven 
isoforms (Sirt1-7) in mammals (8). Their functions are known 
to be associated with metabolic diseases, such as type II 
diabetes and obesity (9, 10). Among the seven isoforms, 
Sirtuin2 (Sirt2) may coordinate the regulation of several 
distinct metabolic processes, including adipocyte differentia-
tion, fatty acid oxidation, hepatic gluconeogenesis, and insulin 
action, as well as the regulation of inflammatory pathways 
(11). Nevertheless, the role of Sirt2 in drug-induced liver injury 
remains unclear. 
In this study, we investigated the role of Sirt2 in 
APAP-induced hepatotoxicity using mouse models in which 
Sirt2 was inactivated genetically and pharmacologically.
RESULTS
APAP decreases Sirt2 levels and Sirt2 ablation ameliorates 
APAP-induced liver injuries in mice
APAP is usually deemed as a safe drug, but APAP intoxication 
after an overdose can cause massive hepatocellular necrosis 
and acute liver injury (2, 4, 5, 12). To investigate whether Sirt2 
plays a role in APAP-induced liver injuries, we first determined 
Sirt2 levels in the mouse liver following treatment with APAP 
for the indicated periods of time. Our results showed that 
APAP treatment induced the degradation of Sirt2 isoforms 1 
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Fig. 1. APAP decreases Sirt2 levels in the mouse liver and ablation of Sirt2 ameliorates APAP-induced liver injuries in mice. (A) The livers 
of mice intraperitoneally injected with vehicle or APAP (500 mg/kg) for the indicated times were isolated, and liver homogenates were 
subjected to immunoblotting for Sirt2 and -actin (loading control). (B) qRT-PCR analysis for the determination of Sirt2 mRNA levels. (C, 
D) Densitometric analysis of immunoblots, similar to those in (A). Ten-week-old WT and Sirt2 KO mice were injected with APAP (500 
mg/kg). (E) Representative images, H&E analysis (magnification, 100×). The small panel images are enlarged photographs from the boxed 
areas (magnification, 200×), Quantitation of necrotic areas on H&E-stained mouse liver sections. (F) TUNEL analysis of liver sections and 
quantitation of TUNEL analysis. (G) Serum levels of alanine transaminase (=GPT). (H) Serum levels of GOP. Investigation of the increased 
hepatotoxicity in mice treated with vehicle, APAP, or AGK2 (Sirt2 inhibitor). Ten-week-old WT and Sirt2 KO mice were injected with 
AGK2 (1 mg/kg) 2 h prior to APAP (500 mg/kg) administration, and plasma and livers were collected 12 h after APAP injection. (I) 
Representative images from H&E analysis and Quantitation of the necrotic area. (J) TUNEL analysis and Quantitation. (K) Serum levels of 
alanine transaminase (=GPT). (L) Serum levels of GOP. Data represent the mean ± SD from three independent experiments. *P ＜ 0.05, 
**P ＜ 0.01, N.S, not significant.
and 2 in the mouse liver (Fig. 1A, 1C, 1D). However, the Sirt2 
mRNA levels were not changed in the same samples (Fig. 1B). 
To verify whether Sirt2 degradation is regulated at the 
translational or post-transcriptional level, we treated normal 
liver cells (AML12 cells) with cycloheximide to inhibit protein 
synthesis and then measured Sirt2 levels in response to 
APAP-induced injuries. Sirt2 degradation was partially blocked 
in cycloheximide-treated AML12 cells (Supplementary Fig. 
1A-1C), indicating that Sirt2 degradation is translationally 
modulated. We further examined whether downregulation of 
Sirt2 by APAP is mediated by the proteasomal or autophagic 
degradation pathway. AML12 cells were treated with an 
autophagy inhibitor (chloroquine, CQ) or a proteasome 
inhibitor (MG132). Immunoblot analysis showed that 
APAP-induced Sirt2 degradation was markedly inhibited by 
MG132 (Supplementary Fig. 1D-1F) and partially degraded by 
CQ (Supplementary Fig. 1G-1I). Taken together, these results 
indicate that APAP-induced downregulation of Sirt2 was 
regulated at the translational level and by the proteasomal 
degradation pathway. To investigate the effect of Sirt2 on 
APAP-induced liver injuries, we examined liver tissues from 
Sirt2 wild-type (WT) and Sirt2 knockout (KO) mice treated 
with APAP or vehicle for 12 h. Furthermore, B6 mice, 
pre-treated with AGK2, the most potent Sirt2 inhibitor (13-15), 
were treated with APAP or vehicle to further examine whether 
the pharmacological inactivation of Sirt2 alleviates APAP- 
induced liver injuries. Subsequently, standard hematoxylin- 
eosin (H&E) staining and TUNEL analysis were performed. 
Histological analyses using H&E staining revealed that normal 
liver displayed prominent liver injuries and necrotic hepatic 
cell death. In contrast, histological sections from both Sirt2 KO 
mice (Fig. 1E) and mice treated with AGK2 (Fig. 1I) showed a 
decrease in the severity of liver injuries and necrotic hepatic 
cell death compared with Sirt2 WT mice in response to APAP. 
Moreover, TUNEL-positive apoptotic cells were scarcely 
detected in the livers of Sirt2 WT and Sirt2 KO mice treated 
with APAP or vehicle for 12 h. Our results showed a 
considerable decrease in the percentage of TUNEL-positive 
cells in the liver of Sirt2 KO mice (Fig. 1F) and mice treated 
with AGK2 (Fig. 1J) in response to APAP. Moreover, Sirt2 KO 
mice treated with APAP and mice treated with AGK2 exhibited 
decreased levels of alanine transaminase (GPT) and aspartate 
transaminase (GOP) in response to APAP (Fig. 1G-1H, 1K-1L). 
Correspondingly, Sirt2 KO mice treated with APAP for 6 h 
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Fig. 2. The inactivation of Sirt2 attenuates ER stress in 
APAP-induced liver injuries in mice. (A-D) The livers of mice 
intraperitoneally injected with vehicle or APAP (500 mg/kg) for 
the indicated times were isolated, and qRT-PCR analysis for the 
determination of Grp78, PERK, ATF4, and IRE1 mRNA levels. 
(E-H) Sirt2 WT or Sirt2 KO mice 12 h after an intraperitoneal 
injected with vehicle or APAP (500 mg/kg). qRT-PCR analysis for 
the determination of Grp78, PERK, ATF4, and IRE1 mRNA 
levels. (I-L) The livers of mice intraperitoneally injected with 
vehicle, APAP (500 mg/kg), and AGK2 (1 mg/kg) for 12 h were 
isolated, and qRT-PCR analysis for the determination of Grp78, 
PERK, ATF4, and IRE1 mRNA levels. Data represent the mean 
± SD from three independent experiments. *P ＜ 0.05.
Fig. 3. The APAP-induced S6K1 phosphorylation is inhibited in 
the livers of Sirt2-inactivated mice. (A) The livers of mice 
intraperitoneally injected with vehicle or APAP (500 mg/kg) for 
the indicated times were isolated, and immunoblot analysis for 
p-S6K1, S6K1, p-S6, and S6. (B, C) Densitometric analysis. (D-F) 
Sirt2 WT or Sirt2 KO mice 12 h after an intraperitoneal injected 
with vehicle or APAP (500 mg/kg), immunoblot analysis for Sirt2, 
p-S6K1, S6K1, p-S6, and S6. Densitometric analysis (D). (G) The 
livers of mice intraperitoneally injected with vehicle, APAP (500 
mg/kg), AGK2 (1 mg/kg) for 12 h were isolated, and immunoblot 
analyses for p-S6K1, S6K1, p-S6, and S6. (H, I) Densitometric 
analysis. Data represent the mean ± SD from three independent 
experiments. *P ＜ 0.05.
showed a substantial decrease in the size of necrotic areas, 
TUNEL-positive cell count, and GPT and GOP levels 
(Supplementary Fig. 2A-2F). Furthermore, we found that the 
level of protein 3-nitrotyrosine, a marker of oxidative stress, 
decreased in Sirt2 KO mice treated with APAP for 12 h 
(Supplementary Fig. 3A, 3B) and 6 h (Supplementary Fig. 4A, 
4B), and in AGK2-treated livers (Supplementary Fig. 5A, 5B), 
compared to that in Sirt2 WT mice. Based on the notion that 
an APAP overdose significantly induces mitochondrial damage 
(16), we provide evidence that the ablation of Sirt2 and 
pharmacological inactivation of Sirt2 alleviate the APAP- 
induced mitochondrial damage, using electron microscopy. In 
the same samples, we found distinctive mitochondrial 
morphological changes, typical necrotic cells with swollen 
mitochondria, accumulation of lipid droplets, and disruption 
of plasma membranes (17) (Supplementary Fig. 3C, 5C). 
Collectively, our data show that the pharmacological 
inactivation of Sirt2 in APAP-treated mouse livers exhibits 
effects similar to those of the pathology that results from the 
ablation of Sirt2. 
The inactivation of Sirt2 attenuates ER stress in APAP-induced 
liver injuries in mice 
It has been reported that APAP can induce ER stress in vivo 
and in vitro and that these deleterious effects can play a 
significant role in the APAP‐induced cell death in the liver (6, 
18-20). Upon acute ER stress, BiP/Grp78 dissociates from 
these sensors, leading to the activation of the unfolded protein 
response pathway, to resolve ER stress and restore homeostasis 
(21). Consistent with this report, we found that ER stress 
marker genes such as BiP/Grp78, PERK, ATF4, and IRE1 were 
also upregulated in the mouse liver (Fig. 2A-2D). To determine 
whether Sirt2 regulates the APAP-mediated increase in ER 
stress, we examined the levels of ER stress markers in Sirt2 WT 
and KO mice treated with APAP. APAP enhanced BiP/Grp78 
levels and downregulated ER stress marker genes in Sirt2 KO 
mice (Fig. 2E-2H) and mice treated with AGK2 (Fig. 2I-2L), as 
assessed by qRT-PCR. Moreover, the short APAP treatment (6 
h) showed a similar effect (Supplementary Fig. 6A-6E). 
Consistent with the notion that ablation of Sirt2 regulates the 
APAP-induced ER stress, these results suggest that inactivation 
of Sirt2 ameliorates the APAP-induced ER stress in the mouse 
liver.
The APAP-induced S6K1 phosphorylation is inhibited in the 
livers of Sirt2-inactivated mice 
The mammalian target of rapamycin complex 1 (mTORC1) has 
been implicated in the regulation of ER stress, and the 
inhibition of mTORC1 may have potential therapeutic effects 
in ER stress-related diseases (22). To investigate whether the 
ablation of Sirt2 ameliorates the APAP-induced ER stress 
through the regulation of the mTORC1 signaling pathway, the 
level of mTOR phosphorylation induced by APAP was 
determined by immunoblot analysis in Sirt2 WT and KO mice. 
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Fig. 4. Sirt2 regulates the phosphorylation of S6K1 through S6K1 
deacetylation in APAP-treated mouse livers. Immunoblots of 
immunoprecipitates and whole-cell lysates from lysates of (A) 
HEK293 cells transfected with S6K1 and Flag-Sirt2 (F-SIRT2) 
vectors subjected to immunoprecipitation with an antibody against 
S6K1. (B) HEK293 cells transfected with an S6K1, F-SIRT2, and a 
Sirt2 (H187Y) catalytic dead mutant vector subjected to immuno-
precipitation with antibodies against acetyllysine, S6K1, or Flag. 
(C) HEK293 cells transfected with an HA-S6K1 (H-S6K1) or a 
Flag-Sirt2 vector subjected to immunoprecipitation with antibodies 
against Flag. (D) HEK293 cells transfected with H-S6K1, F-SIRT2, 
and F-SIRT2 (H187Y) vectors subjected to immunoprecipitation
with antibodies against acetyllysine, or HA. (E) Sirt2 WT or Sirt2 
KO mouse livers, following treatment with APAP for 12 h, 
subjected to immunoprecipitation with an anti-S6K1 antibody. (F) 
Sirt2 WT mouse livers, following treatment with APAP or AGK2 
for 12 h, subjected to immunoprecipitation with an with an 
antibody against S6K1.
Our results indicated that mTOR phosphorylation level did not 
differ between the two groups (Supplementary Fig. 7A-7D). 
S6K1 and ribosomal protein S6 are downstream targets of 
mTORC1. Chronic acetaminophen treatment increased S6K1 
phosphorylation in rat muscles (23). To investigate whether 
Sirt2 regulates the S6K1 signaling pathway, we examined the 
levels of APAP-induced S6K1 phosphorylation in the livers of 
Sirt2 WT and KO mice and mice treated with AGK2. In 
accordance with the results obtained in rats, we observed that 
the phosphorylation of S6K1 and that of the S6 ribosomal 
protein gradually increased in a time-dependent manner 
following APAP treatment in the mouse liver (Fig. 3A-3C). 
Moreover, S6K1 phosphorylation was markedly decreased in 
Sirt2 KO mice treated with APAP for 12 h (Fig. 3D-3F), 6 h 
(Supplementary Fig. 6A, 6B) and in mice treated with AGK2 
(Fig. 3G-3I). These results confirmed that Sirt2 inactivation 
downregulates the APAP-induced ER stress by inhibiting the 
S6K1 signaling pathway. 
Sirt2 regulates S6K1 phosphorylation through S6K1 
deacetylation in APAP-treated mouse livers 
It has been reported that S6K1 acetylation blocks the 
mTORC1-dependent S6K1 phosphorylation at T389, an 
essential phosphorylation site for S6K1 activity and that this 
acetylation is inhibited by Sirt2 (24). Therefore, we explored 
the mechanism underlying the Sirt2-mediated regulation of 
S6K1 acetylation in APAP-treated mouse livers. Firstly, to 
confirm the role of Sirt2 in S6K1 deacetylation, we performed 
a co-immunoprecipitation analysis on HEK293 cells transfected 
with expression vectors for S6K1 or HA-tagged S6K1, together 
with a vector encoding a Flag-tagged Sirt2 (F-SIRT2). 
Consistent with the above report, our results showed that Sirt2 
interacts with S6K1 (Fig. 4A, 4C). Furthermore, to validate that 
S6K1 deacetylation is mediated by Sirt2, we performed an 
acetylation assay coupled with co-immunoprecipitation in 
HEK293 cells transfected with expression vectors for the 
wild-type or a Sirt2 catalytic mutant (H187Y) and S6K1 or 
HA-tagged S6K1. Our results revealed that the Sirt2 catalytic 
mutant did not deacetylate S6K1, as opposed to the wild-type 
Sirt2 (Fig. 4B, 4D). In addition, we observed similar results 
using APAP-treated livers from Sirt2 knockout mice and 
AGK2-pretreated mice (Fig. 4E, 4F). Taken together, these 
results suggest that Sirt2 interacts with and deacetylates S6K1 
to promotes its phosphorylation. 
DISCUSSION
In this study, we found that an APAP overdose decreased the 
expression of two Sirt2 proteins in the mouse liver. A 
sequence analysis, using the GenBank sequence database, 
showed that Sirt2 has four different human splice variants. 
However, only transcript variants 1 and 2 have been verified 
as protein isoforms of physiological relevance (25). 
The observation that APAP may mediate the downregulation 
of Sirt2 proteins (isoforms 1 and 2) led us to investigate the 
role of Sirt2 in APAP-induced liver injuries. Our results 
revealed that the Sirt2 deficiency renders mice less susceptible 
to APAP-induced hepatotoxicity. 
Recent screening campaigns have identified several selective 
inhibitors of Sirt2, including Sirt-rearranging ligands 1 and 2, 
AK-1, AK-7, and AGK2 (26, 27). Of these, AGK2 is the most 
potent inhibitor of Sirt2 (13, 15). Accordingly, we found that 
AGK2 treatment significantly alleviated the APAP-induced 
hepatotoxicity in the mouse liver.
Excessive ER stress results in multiple pathologies, including 
cirrhosis, non-alcoholic fatty liver disease, diabetes mellitus, 
viral inflammation, and cancer (28, 29). Previous studies have 
reported that APAP is able to induce ER stress in vivo and in 
vitro and that this deleterious effect could play a significant 
role in the APAP‐induced cell death in the liver (6, 18-20). Our 
observation that the Sirt2 deficiency attenuates the APAP- 
induced ER stress might explain the protective role of Sirt2 
inactivation in the APAP-induced hepatotoxicity.
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It is widely known that mTORC1 regulates cellular 
processes, protein synthesis, cell growth, and survival through 
the phosphorylation and activation of S6K1 (30). Moreover, 
mTORC1 represents one of the upstream triggers of ER stress; 
hence. the inhibition of mTORC1 may potentially be 
employed in the therapy of ER stress-induced diseases (22). A 
previous study reported that mTOR/S6K signaling is inhibited 
by acetaminophen; however, this study was limited as primary 
mouse hepatocytes were used for the experiments (17, 31). On 
the contrary, there are several reports that S6K1 phosphory-
lation is increased by chronic APAP treatment in rats (23) and 
by APAP overdose in mouse livers (32, 33). Correspondingly, 
our results showed that the ablation of Sirt2 downregulates the 
APAP-induced S6K1 phosphorylation, resulting in an 
attenuation of ER stress. However, the inactivation of Sirt2 has 
no effect on the phosphorylation of mTORC1 (Supplementary 
Fig. 7). These observations suggest that S6K1 may be a specific 
substrate of Sirt2 in this context.
A recent study has shown that the acetylation of S6K1 blocks 
the mTORC1-dependent phosphorylation of S6K1 and that the 
acetylation of S6K1 is inhibited by Sirt2 (24). In agreement 
with this report, we also found that Sirt2 interacts with and 
deacetylates S6K1. Thus, Sirt2 inhibition induces S6K1 
acetylation and subsequently block S6K1 phosphorylation to 
downregulate the APAP-induced ER stress in the mouse liver.
Growing evidence from recent studies indicates that the 
inactivation of Sirt2 has protective roles in liver diseases. For 
example, it has been reported that Sirt2 deficiency might 
attenuate the APAP-induced liver toxicity by downregulating 
c-Jun NH2-terminal kinase (JNK) activation. Furthermore, Sirt2 
aggravates the hepatic ischemia-reperfusion injury through the 
deacetylation and inhibition of mitogen-activated protein 
kinase phosphatase-1 (34). Moreover, Sirt2 accelerates hepatic 
fibrogenesis by regulating the ERK/c-MYC pathway. Therefore, 
the inactivation of Sirt2 may represent an effective strategy for 
protecting against the development of hepatic fibrosis (35). In 
addition, the ablation of the Sirt3 mitochondrial deacetylase 
plays a protective role in APAP-induced hepatotoxicity through 
the activation of mitochondrial aldehyde dehydrogenase 2 (36).
Furthermore, Sirt2 knockdown induces autophagy and 
prevents post-slippage death by abnormally prolonging the 
mitotic arrest induced by microtubule inhibitors (37). 
Moreover, Sirt2 leads to genetic instability and tumorigenesis 
by positively regulating APC/C activity via the deacetylation of 
its coactivators, CDH1 and CDC20 (38, 39). 
The silencing of Sirt2 significantly activates necrosis in PC12 
cells but does not affect autophagy in these cells (40). 
Furthermore, the inhibition of Sirt2 induces p53-dependent 
apoptosis in cancer cells (41). In conclusion, Sirt2 plays 
different roles in various contexts, through the deacetylation of 
specific substrates.
Taken together, we have elucidated the molecular 
mechanism underlying the protective role of Sirt2 inactivation 
in APAP-induced liver injuries. 
MATERIALS AND METHODS
See Supplementary Information for Materials and Methods.
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